PHLDB2 and lung adenocarcinoma: Interestingly, the expression of PHLDB2 was decreased in lung cancer tissues, but showed a mosaic change in various kinds of cancer types in a pan-cancer analysis with TCGA data (with upregulation in HNSC (head and neck squamous cell carcinoma), PAAD (pancreatic adenocarcinoma), DLBC (lymphoid neoplasm diffuse large B-cell lymphoma), and some others, while showed downregulation in LUAD (lung adenocarcinoma) and LUSC (lung squamous cell carcinoma) (Supplementary Figure 1).